Asenapine Therapy in Adolescents With Schizophrenia: Results From a Double-Blind Efficacy Trial and a Long-Term Open-Label Extension Trial

New Research Poster Presentation 6.29
Asenapine Therapy in Adolescents With Schizophrenia: Results From a Double-Blind Efficacy Trial and a Long-Term Open-Label Extension Trial

Saturday, October 25, 2014 10:00 AM

Robert L. Findling, MD, MBA, The Johns Hopkins University/Kennedy Krieger Institute, Baltimore, MD

Ronald Landbloom, MD, Merck, Rahway, NJ

Mary Mackle, PhD, Merck, Whitehouse Station, NJ

Wendi Pallozzi, MS, Merck, Whitehouse Station, NJ

Sabine Braat, Merck, Whitehouse Station, NJ

Armin Szegedi, MD, PhD, Forest Research Institute, Jersey City, NJ

Marianne Zdeblick Wamboldt, MD, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO

Maju Mathews, Forest Research Institute, Jersey City, NJ